Cassava Sciences Publishes Phase 3 Simufilam Results in Alzheimer's Disease, Reveals Biomarker Screening Challenges
核心洞察
Cassava Sciences (搜索) published peer-reviewed results from two Phase 3 trials (RETHINK-ALZ and REFOCUS-ALZ) evaluating simufilam for mild-to-moderate Alzheimer's disease, which failed to meet their primary endpoints.
Post-hoc analyses identified potential treatment benefits in mild Alzheimer's patients, with simufilam 100 mg showing nominally significant cognitive improvements at multiple time points compared to placebo.
The trials revealed significant biomarker screening limitations, with 21% of participants unexpectedly testing amyloid-negative despite plasma p-tau181 (搜索) entry criteria, highlighting challenges in patient selection for Alzheimer's trials.
Cassava Sciences (搜索) has published detailed results from two Phase 3 clinical trials evaluating simufilam in mild-to-moderate Alzheimer's disease, providing valuable insights for the research community despite the trials' failure to meet their primary endpoints. The peer-reviewed analysis, published in the Journal of Prevention of Alzheimer's Disease, offers important lessons about biomarker-based patient selection and potential therapeutic signals in specific patient subgroups.
Trial Design and Outcomes
The Phase 3 RETHINK-ALZ (NCT04994483) and REFOCUS-ALZ (NCT05026177) trials were designed as multi-center, double-blinded, placebo-controlled studies evaluating simufilam compared to placebo across clinical sites in the U.S., Canada, and Asia. RETHINK-ALZ randomly assigned 804 participants with mild to moderate Alzheimer's disease, while REFOCUS-ALZ included 1,125 participants.
Both studies failed to meet their prespecified co-primary endpoints, which included changes in cognition and function from baseline assessed by the ADAS-Cog12 and ADCS-ADL scales. Secondary endpoints measuring neuropsychiatric symptoms and caregiver burden, as well as exploratory biomarker endpoints, were also not achieved.
Signals in Mild Patient Subgroups
Despite the overall negative results, exploratory analyses revealed potential treatment effects in predefined mild patient subgroups (MMSE score 21-27). In REFOCUS-ALZ, simufilam 100 mg was associated with slower cognitive decline than placebo in the mild subgroup, with nominally significant differences at Week 4 and Weeks 28, 40, 52, and 64 (p = 0.01, 0.01, 0.02, 0.02, and 0.02, respectively). However, this potential treatment difference did not replicate in RETHINK-ALZ and was no longer evident at Week 76 of REFOCUS-ALZ, which had 45% missing data due to early study termination.
A prespecified pooled analysis of mild patients from both trials showed potential treatment group differences at weeks 4 and 28 (nominally significant at p < 0.01). An exploratory post hoc analysis using a plasma p-tau181 (搜索) cutoff of ≥67 (the highest half of all patients) showed differences in slowing of decline at Weeks 4, 28, and 40 (nominally significant at p = 0.03, 0.001, 0.006, respectively), with a trend at Week 52 (p = 0.066).
Biomarker Screening Challenges Revealed
These trials marked the first Phase 3 Alzheimer's disease studies to rely primarily on a plasma biomarker (p-tau181 (搜索)) for biological confirmation of disease. However, the research revealed significant limitations in this approach. An amyloid PET sub-study in REFOCUS-ALZ showed that 21% of participants (33 of 160) were unexpectedly amyloid negative at baseline, indicating an absence of Alzheimer's disease pathology.
"This suggests that the plasma p-tau181 (搜索) assay cut-off used as an entry criterion in both trials was insufficient to screen effectively for Alzheimer's disease pathology in trial participants," the authors noted in their publication.
Expert Commentary and Future Implications
Dr. James Kupiec, retired Chief Medical Officer of Cassava and primary publication author, commented: "Exploratory and post hoc analyses identified specific subgroups of patients with an observed treatment difference between the higher dose of simufilam and placebo. While Cassava does not intend to conduct further studies in this indication, we believe these observations are informative."
Dr. Anton Porsteinsson, Director of the University of Rochester's Alzheimer's Disease Research, Care and Education Program, emphasized the scientific value of the publication: "Publication of the results from these large, rigorously designed and conducted Phase 3 studies plays an essential role in shaping future studies and ensuring a complete scientific record for the betterment of drug development and public health."
Company's Strategic Pivot
Based on these results, Cassava has discontinued development of simufilam for Alzheimer's disease and plans no further investment in this indication. However, the company is leveraging the safety data from these trials for their ongoing development program in tuberous sclerosis complex (TSC)-related epilepsy.
Rick Barry, President and CEO of Cassava, stated: "The detailed safety observations reported in the article provide heartening encouragement for our ongoing development program in TSC-related epilepsy, as we work to initiate a proof-of-concept study in collaboration with leading investigators."
About Simufilam
Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A (搜索) protein, which regulates diverse aspects of neuronal development. The company is planning a Phase 2 proof-of-concept study to evaluate simufilam in patients with TSC-related epilepsy, collaborating with the TSC Alliance and key opinion leaders.